Press
New Biomarker for Parkinsons Disease
New Biomarker for Parkinsons Disease
A misfolded protein enables a secure diagnosis in early disease stages.
Go to article
Innovation Price 2023 NRW
Spin-off betaSENSE moves into the BioMedicineCenter
Spin-off betaSENSE moves into the BioMedicineCenter
Mayor Thomas Eiskirch ceremoniously handed over the keys to Managing Director Klaus Gerwert.
Go to article
Publications
EMBO Molecuar Medicine, 2025
EMBO Molecuar Medicine, 2025
Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform
Go to article
Alzheimer’s & Dementia, 2022
Alzheimer’s & Dementia, 2022
Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years
Go to article
Annals of Clinical & Translational Neurology, 2021
Annals of Clinical & Translational Neurology, 2021
TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis
Go to article